Two truncating variants in FANCC and breast cancer risk

Jane E. Carpenter | M. Beckmann | P. Fasching | A. Olshan | A. Børresen-Dale | E. Ziv | C. Vachon | Jingmei Li | K. Czene | P. Hall | A. Hein | J. Olson | F. Couch | H. Brenner | J. Chang-Claude | S. Chanock | M. García-Closas | O. Olopade | A. Wolk | P. Neven | G. Giles | J. Hopper | C. Haiman | E. John | T. Dörk | M. Southey | A. Lophatananon | L. Marchand | D. Easton | P. Kraft | R. Tamimi | G. Rennert | Chen-Yang Shen | D. Lambrechts | J. Peto | E. Khusnutdinova | K. Offit | J. Spinelli | H. Brauch | V. Kristensen | R. Kåresen | P. Hillemanns | J. Long | X. Shu | W. Zheng | A. Ziogas | H. Anton-Culver | P. Guénel | U. Menon | A. Dunning | D. Eccles | D. Evans | S. Bojesen | H. Nevanlinna | D. Kang | N. Bogdanova | R. Tollenaar | P. Devilee | A. Ouweland | R. Milne | U. Hamann | A. Mannermaa | L. Ottestad | K. Muir | S. Lindström | C. Clarke | B. Naume | K. Sahlberg | Sung-Won Kim | D. Mavroudis | J. Dennis | M. Schmidt | M. Bolla | Qin Wang | C. Blomqvist | A. Meindl | R. Schmutzler | H. Flyger | T. Truong | B. Burwinkel | I. Andrulis | A. Mulligan | S. Margolin | M. Hooning | J. Stone | L. Haeberle | A. Ekici | V. Arndt | A. Swerdlow | J. Figueroa | M. Goldberg | P. Radice | P. Peterlongo | S. Manoukian | A. Jakubowska | J. Lubiński | S. Slager | A. Toland | K. Matsuo | Hidemi Ito | S. Teo | M. Hartman | J. Simard | P. Pharoah | M. Eriksson | M. Schoemaker | Grethe I. Grenaker Alnæs | S. Neuhausen | M. Bermisheva | H. Christiansen | T. Park-Simon | D. Torres | R. Balleine | J. Vijai | M. Dwek | W. Tapper | A. Spigelman | F. Canzian | W. Newman | S. Gapstur | J. Geisler | M. Untch | N. Zeps | R. Kaaks | S. Tsugane | Sue-Kyung Park | D. Huo | F. Hogervorst | Jyh‐cherng Yu | K. Aronson | E. Schlichting | D. Schindler | M. U. Rashid | M. Troester | T. Chan | D. Plaseska-Karanfilska | Elena Martinez | M. Ruebner | A. Morey | W. Janni | M. Daly | A. Fosså | A. Jung | M. Manoochehri | Camilla Wendt | J. Forbes | D. Goldgar | O. Engebråten | Å. Helland | V. Haakensen | Stella Koutros | J. García-Saenz | L. Fritschi | M. Terry | M. Iwasaki | M. Linet | H. Rennert | Christopher Scott | N. Håkansson | G. Torres-Mejía | M. Gago-Domínguez | Ji-Yeob Choi | C. Kitahara | H. Olsson | M. Gabrielson | M. Gaudet | A. Kwong | A. Romero | T. Ahearn | S. Behrens | W. Lo | N. Presneau | B. Rack | E. Saloustros | A. Beeghly-Fadiel | N. A. Mohd Taib | H. Surowy | Peter Simpson | N. Pathmanathan | P. Kapoor | S. Smichkoska | M. Holmen | J. Hauke | Chi Gao | M. Riis | S. Braye | N. Wilcken | T. Howell | Michael O. Schneider | A. Augustinsson | E. M. Veen | K. Reinertsen | C. Kiserud | D. Yip | L. Freeman | E. Pohl-Rescigno | I. dos-Santos-Silva | Torill Sauer | Deb Marsh | R. Baxter | Rodney J. Scott | Rosemary Robert Stephen Jane Jane John C. Soon Deborah Adri Balleine Baxter Braye Carpenter Dahlstro | J. Dahlstrom | C. S. Lee | Anne-Lise Grethe I. Kristine K. Lars Rolf Ellen Marit Muri T Børresen-Dale Grenaker Alnæs Sahlberg O | J. Stone | Thérèse Truong | P. Hall | D. Evans | Qin Wang | Thérèse Truong | D. Plaseska‐Karanfilska | Diana Torres | D. Evans

[1]  G. Nalepa,et al.  Fanconi anaemia and cancer: an intricate relationship , 2018, Nature Reviews Cancer.

[2]  J. Soulier,et al.  Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia , 2017, Genetics in Medicine.

[3]  J. Benítez,et al.  Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility , 2017, Genetics in Medicine.

[4]  Gary D Bader,et al.  Association analysis identifies 65 new breast cancer risk loci , 2017, Nature.

[5]  Michael Jones,et al.  Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer , 2017, Nature Genetics.

[6]  Minoru Takata,et al.  Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia , 2017, The Journal of clinical investigation.

[7]  Lara E Sucheston-Campbell,et al.  Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene , 2017, Oncotarget.

[8]  K. Hodaňová,et al.  Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2‐negatively tested breast cancer patients , 2016, Clinical genetics.

[9]  A. D’Andrea,et al.  The Fanconi anaemia pathway: new players and new functions , 2016, Nature Reviews Molecular Cell Biology.

[10]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[11]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[12]  Eliseos J. Mucaki,et al.  FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. , 2015, Human molecular genetics.

[13]  F. Couch,et al.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer , 2014, Proceedings of the National Academy of Sciences.

[14]  T. Dörk,et al.  Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe , 2014, Familial Cancer.

[15]  J. Benítez,et al.  Evaluation of Rare Variants in the New Fanconi Anemia Gene ERCC4 (FANCQ) as Familial Breast/Ovarian Cancer Susceptibility Alleles , 2013, Human mutation.

[16]  Henk M. W. Verheul,et al.  Analysis of the Novel Fanconi Anemia Gene SLX4/FANCP in Familial Breast Cancer Cases , 2013, Human mutation.

[17]  R. Tothill,et al.  Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles , 2012, PLoS genetics.

[18]  K. Offit,et al.  Heterozygous Mutations in DNA Repair Genes and Hereditary Breast Cancer: A Question of Power , 2012, PLoS genetics.

[19]  C. Begg,et al.  Rare germline mutations in PALB2 and breast cancer risk: A population‐based study , 2012, Human mutation.

[20]  Daniel J. Park,et al.  A PALB2 mutation associated with high risk of breast cancer , 2010, Breast Cancer Research.

[21]  T. Dörk,et al.  PALB2 mutations in German and Russian patients with bilateral breast cancer , 2010, Breast Cancer Research and Treatment.

[22]  Ana Osorio,et al.  Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. , 2009, Carcinogenesis.

[23]  H. Nevanlinna,et al.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.

[24]  J. Satagopan,et al.  Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. , 2007, Cancer research.

[25]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[26]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[27]  S. Seal,et al.  Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. , 2003, Cancer research.

[28]  H. Joenje,et al.  Sequence variations in the Fanconi anaemia gene, FAC: pathogenicity of 1806insA and R548X and recognition of D195V as a polymorphic variant , 1996, Human Genetics.

[29]  C. Mathew,et al.  Genetic mapping of the FACC gene and linkage analysis in Fanconi anaemia families. , 1994, Journal of medical genetics.

[30]  C. Mathew,et al.  Mutation analysis of the Fanconi anemia gene FACC. , 1994, American journal of human genetics.

[31]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[32]  C. Mathew,et al.  FACC gene mutations and early prenatal diagnosis of Fanconi's anaemia , 1993, The Lancet.

[33]  C. Mathew,et al.  A nonsense mutation and exon skipping in the Fanconi anaemia group C gene. , 1993, Human molecular genetics.

[34]  W. R. Shannon,et al.  Cloning of cDNAs for Fanconi's anaemia by functional complementation , 1992, Nature.

[35]  P. Jacobs,et al.  Fanconi's anemia. A family study with 20‐year follow‐up including associated breast pathology , 1984, Cancer.

[36]  M. Swift,et al.  Reassessment of cancer predisposition of Fanconi anemia heterozygotes. , 1980, Journal of the National Cancer Institute.

[37]  Bessie Head,et al.  A question of power , 1973 .

[38]  M. Swift.  Fanconi's Anaemia in the Genetics of Neoplasia , 1971, Nature.